pakisagot need ko po ngayon bigyan ko kayo 5 star and brainlasint
Home
/
pakisagot need ko po ngayon bigyan ko kayo 5 star and brainlasint
pakisagot need ko po ngayon bigyan ko kayo 5 star and brainlasint
Sign Up to our social questions and Answers Engine to ask questions, answer people’s questions, and connect with other people.
Login to our social questions & Answers Engine to ask questions answer people’s questions & connect with other people.
SARS-CoV-2—the causative agent of COVID-19—is a member of the highly diverse coronavirus family, named for the crown-like spikes present on their surface.1-3 Like other members of this virus family, SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus.1
SARS-CoV-2—the causative agent of COVID-19—is a member of the highly diverse coronavirus family, named for the crown-like spikes present on their surface.1-3 Like other members of this virus family, SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus.1 There are several key stages in the SARS-CoV-2 life cycle, including binding, entry, proteolysis, RNA replication, and exit.1,3,4 Understanding the full viral life cycle may shed light on current therapies and potential therapeutic targets at each stage.2,3 Monoclonal antibodies can be used to interfere with SARS-CoV-2 entry into the host cell, and RNA replication may be decreased through use of nucleoside analogs. Halting viral replication by inhibiting proteolysis by a protease inhibitor is another area of interest.2-4
SARS-CoV-2—the causative agent of COVID-19—is a member of the highly diverse coronavirus family, named for the crown-like spikes present on their surface.1-3 Like other members of this virus family, SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus.1 There are several key stages in the SARS-CoV-2 life cycle, including binding, entry, proteolysis, RNA replication, and exit.1,3,4 Understanding the full viral life cycle may shed light on current therapies and potential therapeutic targets at each stage.2,3 Monoclonal antibodies can be used to interfere with SARS-CoV-2 entry into the host cell, and RNA replication may be decreased through use of nucleoside analogs. Halting viral replication by inhibiting proteolysis by a protease inhibitor is another area of interest.2-4Binding and Entry
SARS-CoV-2—the causative agent of COVID-19—is a member of the highly diverse coronavirus family, named for the crown-like spikes present on their surface.1-3 Like other members of this virus family, SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus.1 There are several key stages in the SARS-CoV-2 life cycle, including binding, entry, proteolysis, RNA replication, and exit.1,3,4 Understanding the full viral life cycle may shed light on current therapies and potential therapeutic targets at each stage.2,3 Monoclonal antibodies can be used to interfere with SARS-CoV-2 entry into the host cell, and RNA replication may be decreased through use of nucleoside analogs. Halting viral replication by inhibiting proteolysis by a protease inhibitor is another area of interest.2-4Binding and EntryCoronaviruses, including SARS-CoV-2, can impact many organs, but typically infect the respiratory and gastrointestinal tracts.1 The specific glycoprotein spike structure of SARS-CoV-2 binds to angiotensin-converting enzyme 2 (ACE2) receptors, which along with host proteases mediate cell entry. Spike protein mutations occur frequently, which may increase both binding to ACE2 receptors and entry efficiency.4,5
SARS-CoV-2—the causative agent of COVID-19—is a member of the highly diverse coronavirus family, named for the crown-like spikes present on their surface.1-3 Like other members of this virus family, SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus.1 There are several key stages in the SARS-CoV-2 life cycle, including binding, entry, proteolysis, RNA replication, and exit.1,3,4 Understanding the full viral life cycle may shed light on current therapies and potential therapeutic targets at each stage.2,3 Monoclonal antibodies can be used to interfere with SARS-CoV-2 entry into the host cell, and RNA replication may be decreased through use of nucleoside analogs. Halting viral replication by inhibiting proteolysis by a protease inhibitor is another area of interest.2-4Binding and EntryCoronaviruses, including SARS-CoV-2, can impact many organs, but typically infect the respiratory and gastrointestinal tracts.1 The specific glycoprotein spike structure of SARS-CoV-2 binds to angiotensin-converting enzyme 2 (ACE2) receptors, which along with host proteases mediate cell entry. Spike protein mutations occur frequently, which may increase both binding to ACE2 receptors and entry efficiency.4,5Once the virus releases its RNA into the host cell, translation begins immediately utilizing the host cell ribosomes.1,4 Translation forms two
Answer:
scanning po yan ang sagot thank you